205 related articles for article (PubMed ID: 36723792)
21. Human monoclonal single-chain antibodies specific to dengue virus envelope protein.
Saokaew N; Poungpair O; Panya A; Tarasuk M; Sawasdee N; Limjindaporn T; Chaicumpa W; Yenchitsomanus P
Lett Appl Microbiol; 2014 Mar; 58(3):270-7. PubMed ID: 24266517
[TBL] [Abstract][Full Text] [Related]
22. Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses.
Coffman JE; Metz SW; Brackbill A; Paul M; Miley MJ; DeSimone J; Luft JC; de Silva A; Tian S
Bioconjug Chem; 2018 May; 29(5):1544-1552. PubMed ID: 29701995
[TBL] [Abstract][Full Text] [Related]
23. Production and immunogenicity of Fubc subunit protein redesigned from DENV envelope protein.
Rathore AS; Sarker A; Gupta RD
Appl Microbiol Biotechnol; 2020 May; 104(10):4333-4344. PubMed ID: 32232529
[TBL] [Abstract][Full Text] [Related]
24. [Preparation and identification of neutralizing antibodies to envelope protein domain III(ED III) of the four dengue virus serotypes].
Ding X; Qiu L; Chen Y; Wen K
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Aug; 38(8):748-753. PubMed ID: 35851089
[TBL] [Abstract][Full Text] [Related]
25. Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli.
Yang J; Zhang J; Chen W; Hu Z; Zhu J; Fang X; Yuan W; Li M; Hu X; Tan Y; Hu F; Rao X
Can J Microbiol; 2012 Apr; 58(4):369-80. PubMed ID: 22420529
[TBL] [Abstract][Full Text] [Related]
26. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.
Williams KL; Wahala WM; Orozco S; de Silva AM; Harris E
Virology; 2012 Jul; 429(1):12-20. PubMed ID: 22537810
[TBL] [Abstract][Full Text] [Related]
27. Mice immunized with trimethyl chitosan nanoparticles containing DENV-2 envelope domain III elicit neutralizing antibodies with undetectable antibody-dependent enhancement activity.
Seesen M; Jearanaiwitayakul T; Limthongkul J; Sunintaboon P; Ubol S
J Gen Virol; 2022 Jul; 103(7):. PubMed ID: 35833704
[TBL] [Abstract][Full Text] [Related]
28. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
29. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
[TBL] [Abstract][Full Text] [Related]
30. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
[TBL] [Abstract][Full Text] [Related]
31. Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
Brien JD; Austin SK; Sukupolvi-Petty S; O'Brien KM; Johnson S; Fremont DH; Diamond MS
J Virol; 2010 Oct; 84(20):10630-43. PubMed ID: 20702644
[TBL] [Abstract][Full Text] [Related]
32. Combinatorial Resurfacing of Dengue Envelope Protein Domain III Antigens Selectively Ablates Epitopes Associated with Serotype-Specific or Infection-Enhancing Antibody Responses.
Remmel JL; Beauchemin KS; Mishra AK; Frei JC; Lai JR; Bailey-Kellogg C; Ackerman ME
ACS Comb Sci; 2020 Sep; 22(9):446-456. PubMed ID: 32574486
[TBL] [Abstract][Full Text] [Related]
33. Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies.
Contreras M; Stuart JB; Levoir LM; Belmont L; Goo L
mBio; 2024 Feb; 15(2):e0304823. PubMed ID: 38193697
[TBL] [Abstract][Full Text] [Related]
34. Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.
Khetarpal N; Shukla R; Rajpoot RK; Poddar A; Pal M; Swaminathan S; Arora U; Khanna N
Am J Trop Med Hyg; 2017 Jan; 96(1):126-134. PubMed ID: 27821688
[TBL] [Abstract][Full Text] [Related]
35. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.
Gallichotte EN; Widman DG; Yount BL; Wahala WM; Durbin A; Whitehead S; Sariol CA; Crowe JE; de Silva AM; Baric RS
mBio; 2015 Oct; 6(5):e01461-15. PubMed ID: 26463165
[TBL] [Abstract][Full Text] [Related]
36.
Shukla R; Rajpoot RK; Arora U; Poddar A; Swaminathan S; Khanna N
Front Microbiol; 2017; 8():2644. PubMed ID: 29367852
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
[TBL] [Abstract][Full Text] [Related]
38. Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity.
Park J; Lee HY; Khai LT; Thuy NTT; Mai LQ; Jang YS
Vaccines (Basel); 2020 Feb; 8(1):. PubMed ID: 32075300
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.
Arora U; Tyagi P; Swaminathan S; Khanna N
J Nanobiotechnology; 2012 Jul; 10():30. PubMed ID: 22794664
[TBL] [Abstract][Full Text] [Related]
40. DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.
García-Machorro J; López-González M; Barrios-Rojas O; Fernández-Pomares C; Sandoval-Montes C; Santos-Argumedo L; Villegas-Sepúlveda N; Gutiérrez-Castañeda B; Cedillo-Barrón L
Hum Vaccin Immunother; 2013 Nov; 9(11):2326-35. PubMed ID: 23880886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
